FirstWord

The ALK2 inhibitor approval comes just weeks after US regulators greenlit Regeneron's Pasatru for fibrodysplasia ossificans progressiva.

City Therapeutics joined the IPO queue, just a few months after bagging close to $100 million in a series B.

The nod expands Gazyva beyond its established uses in blood cancers and follows its October approval for active lupus nephritis.

The authorisation of Nezglyal under "exceptional circumstances" for boys with Gd-negative brain lesions follows a 2024 negative CHMP opinion.

Of the 20 patients with relapsed or refractory multiple myeloma (MM) who received a single infusion of J&J and Legend's CAR-T therapy, 10 were alive after five years, with no disease progression.

Having achieved weight loss on par with bariatric surgery, Eli Lilly's retatrutide has set a new efficacy benchmark for obesity drugs. Physicians who spoke with FirstWord for a new Therapy Trends report on the obesity landscape say that given the triple agonist's flexible dosing profile and potentia

As the European Association for the Study of Diabetes (EASD) meeting approaches, FirstWord checks in on whether Western pharmas are running out of Chinese assets to in-license in metabolic disease.

Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its...

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model -  Combination of SLS009 and daraxonrasib ...

— Retrospective analysis of 102 patients from the pivotal FUMANBA-1 study who had achieved MRD negativity: durable in vivo persistence of FUCASO CAR-T cells (assessed by peripheral blood vector copy n...